We are career venture capitalists, biotech founders, former pharma and biotech executives, research scientists, medical doctors, and experienced drug developers. What unites us is the passion for biotech start-ups, innovation and the quest for new and better medicines.
Venture capital investor since 2001, joined Bellevue in 2004. Co-founder and former Executive Chairman of Vaximm, a Swiss-German immuno-oncology company. Prior to Bellevue, Investment Manager at GLS Ventures in Munich. He has invested in a number of bio-pharmaceutical companies, such as Cadence, Glycart, Intercell, Vaximm and AM-Pharma. PhD Molecular Biologist & Chemist.
Former Founder & CEO of ESBATech, a Swiss biotech focusing on next generation antibody drugs. Alcon acquired ESBATech for USD 589 mn in 2009. Subsequently until 2016 Vice President of Alcon R&D. Member of the Global Ophthalmology Leadership and Global Biologics Leadership of Novartis Institutes of Biomedical Research. Since 2002 on the Board of the Swiss Biotech Association.
Venture capital investor since 1999, investing in life science companies across all stages and types. Joined Bellevue Group in 2004. Martin’s investments and board assignments include Bellevue’s most successful private biopharmaceutical investments, such as Radius Health, Molecular Partners, Optimer, Axovan and Glycart. PhD Protein Chemist & Biochemist.
Experienced Scientist, Entrepreneur and Drug Developer in Neuroscience and various Rare Diseases. Over the last 4 years Anja was an Investment Director at the Roche Venture Fund sourcing, leading and managing global investments in various areas and stages like Black Diamond, Vivet, Entrada and NMD. PhD Neuroscienist & Biochemist, MBA
Entrepreneur in Residence
Former business development manager at F. Hoffmann-La Roche AG. Pharmacologist with more than 20 years experience in R&D and partnering in pharma, 16 years at global level. Particular expertise in neuroscience, ophthalmology, and rare diseases. Ph.D. Veterinary Medicine and Executive MBA from ESSEC Paris & Mannheim Business School.
Entrepreneur in Residence
Former CEO Algobate AG, before that in partnering at F. Hoffmann-La Roche AG, Corporate Development at ALTANA Pharma AG and Strategic Planning at Sandoz International, R&D at LION Bioscience AG. 20 years in industry and last 10 years in CEO and business development roles. Particular expertise in inflammation, autoimmune and fibrotic diseases. PhD in Biochemistry at MPI Leipzig.
Chief Medical Officer and Head of Research and Development of Voyager Therapeutics. Previously Global Head of Neuroscience Translational Medicine and Rare Diseases at Roche, and before that Chief Resident at Harvard Medical School. MD Ph.D. from the University of Cambridge, UK.
Former President & CEO of GPC Biotech, NASDAQ listed oncology company. He built the company from a pre-clinical stage to a phase 3 clinical oncology company. Prior to that VP Oncology drug discovery at Bristol-Myers Squibb. Senior Faculty positions at Harvard Medical School, Massachusetts General Hospital and Princeton University.
Former EVP, COO and board director of Cellectis, a premier CAR T-cell and DNA editing company, NASDAQ listed (CLLS). Prior to that, Head of Global Pharmaceutical Operations at Pierre Fabre and in senior corporate and regional roles at Wyeth (US and Europe). Medical Doctor.